• Journal of Microbiology and Biotechnology
• /
• v.8 no.2
• /
• pp.188-190
• /
• 1998

Penicillide, having a 5H, 7H-dibenzo［b,g］［1,5］ dioxocin-5-one skeleton, was isolated from the culture broth of Penicillium sp. F60760 as a nonpeptide inhibitor of calpain, a calcium-activated papain-like protease. The $IC_50$ value for the effect of penicillide against m-calpaln was $7.1{\mu}M$. However, penicillide did not inhibit papain at a concentration of $200{\mu}M$. These results suggest that penicillide is a new class of nonpeptide calpain inhibitor having an eight membered lactone ring.

• Bulletin of the Korean Chemical Society
• /
• v.32 no.4
• /
• pp.1249-1252
• /
• 2011

Inhibition of BACE 1 activity is considered as a promising therapeutic target for Alzheimer's Disease (AD). Synthesis and inhibitory activities of (4-arylpiperazinyl)piperidines by bioisosteric replacement of a biaryl group with an arylpiperazine as BACE 1 inhibitors are described. The resulting (4-arylpiperazinyl)piperidines represent novel nonpeptide BACE 1 inhibitors with improved in vitro potency.

• Bulletin of the Korean Chemical Society
• /
• v.30 no.2
• /
• pp.291-292
• /
• 2009

• Proceedings of the PSK Conference
• /
• 2003.10b
• /
• pp.176.1-176.1
• /
• 2003

Bradykinin is an autocoid related to acute and chronic pain and inflammation. The non-peptide bradykinin antagonists are of interest as novel anti-inflammatory therapeutics. To understand the structural basis for the bradykinin antagonistic activity and to guide the design of more potent compounds we analysed the three dimensional pharmacophore model. Seven active compounds very recently reported such as FR 167344, FR 173657, LF 160687, and bradyzide were used as our pharmacophore model analysis. (omitted)

• Bulletin of Food Technology
• /
• v.15 no.2
• /
• pp.3-24
• /
• 2002

펩타이드와 단백질은 전사, 번역, 후번역 단계에 걸친 모든 생물학적 반응을 조절한다. 그러나 분자수준에서 구조와 기능에 대한 우리의 이해는 초보적인 수준이다. 구조와 기능의 연관성에 대한 문제는 펩타이드와 단백질 자체에 대한 것과는 좀 다르다는 것을 명확히 할 필요가 있다. Multidomain을 갖는 단백질은 작고 통합적이며, 구조적으로 제한된 부분으로 쪼개는 것은 천연 단백질의 활성을 모방하여 저분자의 nonpeptide를 설계하는데 있어서 주요한 일이다. 결정적인 역할을 수행하는 domain을 모방하는 것은 특이성과 치료 효과에 있어서 자연적으로 얻어지는 단백질 물질과 비교하여 이로운 특성을 갖을 수 있고 분자 인지 분야에 관한 연구에 유용한 단서를 제공한다(Chen etal., 1992). 한편 펩타이드는 환경에 의해 구조가 심하게 영향을 받아 특성이 쉽게 변한다(Marshall et al., 1978). 수용액 내에서 이러한 구조적 유동성 때문에 그들이 결합할 수용체나 생리활성을 띄는 구조를 결정하는 것은 어렵고 복잡한 일이다(Fauchre,1987; Hruby, 1987). 구조를 한정하면 이러한 결정을 매우 쉽게 할 수 있다(Hrubyet al., 1987). 단백질 모방학은 분자지각 연구에 강력한 수단이며, 복잡한 단백질과 펩타이드의 구조-기능관계를 탐구하고 분석하는데 독특한 방법이다. 이 장에서는 매우넓고 빠르게 확장되고 있는 Peptidomimetic연구를 간략히 소개하고 있다. 단 본문은 기술 범위를 N-Methylated 아미노산과 스테로이드 등으로 제한하여 소개한다.

• Proceedings of the PSK Conference
• /
• 2002.04a
• /
• pp.111.2-112
• /
• 2002

• YAKHAK HOEJI
• /
• v.58 no.1
• /
• pp.16-20
• /
• 2014

KR-31064 was developed for the strong angiotensin II receptor antagonist among the one of pyridyl imidazol series compounds. To investigate the receptor-ligand binding characteristics of this nonpeptide antagonist, binding experiments were deployed in various conditions and ex vivo contractile responses were tested toward the standard compound, losartan. Receptor binding experiments with radiolabeled angiotensin II, the $IC_{50}$ value for KR-31064 resulted 0.67 nM without any activities toward type 2 angiotensin II receptor. The comparative potency against losartan was more than 18 fold and the specific activity in type 1 angiotensin II receptor was more than 10,000 fold comparing to the type 2 receptor. Scatchard analysis of saturation binding data showed KR-31064 acted on the receptor in a competitive mode. KR-31064 inhibited the contractile response derived by angiotensin II ($pK_B$: 9.86) similar to that of losartan with decreased maximum signals. As a potent and specific type 1 angiotensin II receptor antagonist, KR-31064 may have possibilities for the development of diagnostic ligands that can be used as tools for various biochemical research experiments and non-invasive diagnostics.

• Proceedings of the PSK Conference
• /
• 2003.10a
• /
• pp.91-91
• /
• 2003

The beta-turn has been implicated as an important conformation for biological recognition of peptides or proteins. We adapted the concept of general Ca atom positioning from the cluster analysis and recombination of each ideal beta-turn conformation pattern by Garland and Dean (1. Computer-Aided Molecular Design, 1999, 13, 469) as one strategy of designing non-peptide beta-turn scaffolds. (omitted)

• Journal of the Korea Academia-Industrial cooperation Society
• /
• v.10 no.10
• /
• pp.2997-3003
• /
• 2009

The pharmacological profile of KR-31081, a nonpeptide $AT_1$ selective angiotensin receptor antagonist, was investigated by receptor binding studies, functional in vitro assays with rabbit aorta. KR-31081 inhibited the specific binding of $[^{125}I]\;[Sar^1,\;Ile^8]$-angiotensin II to human recombinant $AT_1$ receptor with an 8.6-fold greater potency than losartan ($IC_{50}$: 1.43 and 12.3 nM, respectively), but it did not inhibit the binding of [$^{125}I$] CGP 42112A to human recombinant $AT_2$ receptor ($IC_{50}$: higher than $10{\mu}M$ for both). The Hill coefficient for the competition curve of KR-31081 against $AT_1$ receptor was not significantly different from unity (0.99). Scatchard analysis showed that KR-31081 interacted with human recombinant $AT_1$ receptor in a competitive manner, as with losartan. In functional studies with rabbit aorta, KR-31081 competitively inhibited the contractile response to angiotensin II ($pK_B$ values: 8.66) with 20-70% decrease in the maximum contractile responses, unlike losartan that showed competitive antagonism without any change in the maximum contractile responses to angiotensin II ($pA_2$ values: 7.59). These results suggest that KR-31081 is a highly potent $AT_1$ selective angiotensin II receptor antagonist with a mode of insurmountable antagonism to be developed as the exploratory potential of this compound.

• Biomolecules & Therapeutics
• /
• v.18 no.2
• /
• pp.152-158
• /
• 2010

Melanin concentrating hormone is a neuropeptide highly expressed in the brain that regulates several physiological functions mediated by receptors in the G-protein coupled receptor family, especially plays an important role in the complex regulation of energy balance and body weight mediated by the melanin concentrating hormone receptor subtype 1 (MCH1). Compelling pharmacological evidence implicating MCH1 signaling in the regulation of food intake and energy expenditure has generated a great deal of interest by pharmaceutical companies as MCH1 antagonists may have potential therapeutic benefit in the treatment of obesity and metabolic syndrome. Although fluorescence-based calcium mobilization assay platform has been one of the most widely accepted tools for receptor research and drug discovery, fluorescence interference and shallow assay window limit their application in high throughput screening and have led to a growing interest in alternative, luminescence-based technologies. Herein, a luminescence-based functional assay system for the MCH1 receptor was developed and validated with the mitochondrial targeted aequorin. Aequorin based functional assay system for MCH1 presented excellent Z' factor (0.8983) and high signal-to-noise ratio (141.9). The nonpeptide MCH1 receptor antagonist, SNAP 7941 and GSK 803430, exhibited $IC_{50}$ values of 0.62 ${\pm}$ 0.11 and 12.29 ${\pm}$ 2.31 nM with excellent correlation coefficient. These results suggest that the aequorin based assay system for MCH1 is a strong alternative to the traditional GPCR related tools such as radioligand binding experiments and fluorescence functional determinations for the compound screening and receptor research.